Display options
Cite
Leeming DJ, Willumsen N, Sand JMB, et al. A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis. Biochem Biophys Rep. 2018;17:38-43doi: 10.1016/j.bbrep.2018.11.002.
Leeming, D. J., Willumsen, N., Sand, J. M. B., Holm Nielsen, S., Dasgupta, B., Brodmerkel, C., Curran, M., Bager, C. L., & Karsdal, M. A. (2019). A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis. Biochemistry and biophysics reports, 1738-43. https://doi.org/10.1016/j.bbrep.2018.11.002
Leeming, D J, et al. "A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis." Biochemistry and biophysics reports vol. 17 (2019): 38-43. doi: https://doi.org/10.1016/j.bbrep.2018.11.002
Leeming DJ, Willumsen N, Sand JMB, Holm Nielsen S, Dasgupta B, Brodmerkel C, Curran M, Bager CL, Karsdal MA. A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis. Biochem Biophys Rep. 2018 Nov 30;17:38-43. doi: 10.1016/j.bbrep.2018.11.002. eCollection 2019 Mar. PMID: 30555938; PMCID: PMC6276730.
Copy Download .nbib Format: NLM
Share it on

Biochem Biophys Rep. 2018 Nov 30;17:38-43. doi: 10.1016/j.bbrep.2018.11.002. eCollection 2019 Mar.

A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis.

Biochemistry and biophysics reports

D J Leeming, N Willumsen, J M B Sand, S Holm Nielsen, B Dasgupta, C Brodmerkel, M Curran, C L Bager, M A Karsdal

Affiliations

  1. Nordic Bioscience A/S, Biomarkers and Research, Herlev, Denmark.
  2. Janssen Research and Development, LLC, Spring House, PA, USA.
  3. Proscion, Herlev, Denmark.

PMID: 30555938 PMCID: PMC6276730 DOI: 10.1016/j.bbrep.2018.11.002

Abstract

OBJECTIVES: Lysyl oxidase like 2 (LOXL2) is associated with poor prognosis in idiopathic pulmonary disease (IPF) and cancer. We developed an Enzyme-linked immunosorbent assay (ELISA) targeting the LOXL2 neo-epitope generated through the release of the signal peptide during LOXL2 maturation.

DESIGN AND METHODS: An ELISA targeting the N-terminal site of the human LOXL2 was developed including technical optimization and validation steps. Serum LOXL2 was measured in patients with breast, colorectal, lung, ovarian, pancreatic and prostate cancer, melanoma, IPF and in healthy controls (n = 16).

RESULTS: A technically robust and specific assay was developed. LOXL2 was detectable in serum from healthy controls and showed reactivity towards recombinant LOXL2. Compared to controls, LOXL2 levels were significantly (p < 0.001-0.05) elevated in serum from patients with breast, colerectal, lung, ovarian and pancreatic cancer (mean range: 49-84 ng/mL), but not in prostate cancer (mean: 36 ng/mL) and malignant melanoma patients (41 ng/mL). Serum LOXL2 was elevated in IPF patients compared to healthy controls (mean: 76.5 vs 46.8 ng/mL; p > 0.001).

CONCLUSIONS: A specific ELISA towards the N-terminal neo-epitope site in LOXL2 was developed which detected significantly elevated serum levels from patients with above-mentioned cancer types or IPF compared to healthy controls.

Keywords: AUROC, area under the receiver operating characteristics; Cancer; Extracellular matrix; Idiopathic pulmonary fibrosis; LLOD, lower limit of detection; LLOQ, lower limit of quantification; Lysyl Oxidase like-2; Neoepitope; Serological biomarker; ULOD, upper limit of detection

References

  1. Thorax. 1999 Sep;54(9):805-12 - PubMed
  2. Trends Biochem Sci. 2000 Mar;25(3):147-50 - PubMed
  3. Biochem J. 2001 Apr 15;355(Pt 2):381-7 - PubMed
  4. J Invest Dermatol. 2001 Aug;117(2):269-73 - PubMed
  5. Prog Nucleic Acid Res Mol Biol. 2001;70:1-32 - PubMed
  6. Anat Rec A Discov Mol Cell Evol Biol. 2003 Dec;275(2):1073-80 - PubMed
  7. Biochem Biophys Res Commun. 2004 Aug 20;321(2):413-23 - PubMed
  8. Cancer Res. 2008 Jun 15;68(12):4541-50 - PubMed
  9. Physiol Rev. 2009 Jul;89(3):991-1023 - PubMed
  10. Clin Biochem. 2010 Jul;43(10-11):793-804 - PubMed
  11. J Biol Chem. 2010 Jul 2;285(27):20964-74 - PubMed
  12. Nat Med. 2010 Sep;16(9):1009-17 - PubMed
  13. Biomarkers. 2011 May;16(3):193-205 - PubMed
  14. Eur Respir J. 2014 May;43(5):1430-8 - PubMed
  15. Hepatology. 2014 Nov;60(5):1645-58 - PubMed
  16. Bioorg Chem. 2014 Dec;57:231-41 - PubMed
  17. Respiration. 2014;88(6):487-99 - PubMed
  18. Lancet Respir Med. 2017 Jan;5(1):22-32 - PubMed
  19. Connect Tissue Res. 1985;14(2):109-19 - PubMed
  20. J Pharmacol Exp Ther. 1981 Dec;219(3):675-8 - PubMed
  21. Pulm Pharmacol Ther. 1998 Apr-Jun;11(2-3):221-5 - PubMed

Publication Types